Targeted therapies: how personal should we go? (Q37956110)

25 August 2017

title

Targeted therapies: how personal should we go? (English)

1 reference

25 August 2017

4

Sabine Tejpar

0 references

Miriam Martini

object named as

Miriam Martini

1

0 references

Alberto Bardelli

object named as

Alberto Bardelli

5

0 references

Salvatore Siena

object named as

Salvatore Siena

3

0 references

author name string

Loredana Vecchione

2

1 reference

25 August 2017

language of work or name

English

0 references

publication date

15 November 2011

1 reference

Nature Reviews Clinical Oncology

25 August 2017

published in

1 reference

25 August 2017

volume

9

1 reference

25 August 2017

issue

2

1 reference

25 August 2017

page(s)

87-97

1 reference

Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Prognostic Role of ERCC1 in Advanced Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

The genomic landscapes of human breast and colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Lessons from hereditary colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Cancer driver mutations in protein kinase genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

PDGFRA activating mutations in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

HER2 and responsiveness of breast cancer to adjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Future issues in highly conformal radiotherapy for head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Association of epidermal growth factor receptor (EGFR) gene mutations with EGFR amplification in advanced non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

New driver mutations in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Screening for epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Genomic and biological characterization of exon 4 KRAS mutations in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Recurrent KRAS codon 146 mutations in human colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Relationship among guanine nucleotide exchange, GTP hydrolysis, and transforming potential of mutated ras proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Detection of codon 12 K-ras mutations in non-neoplastic mucosa from bronchial carina in patients with lung adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Ink4a/Arf and oncogene-induced senescence prevent tumor progression during alternative colorectal tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

APC, signal transduction and genetic instability in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCLINONC.2011.164

Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22083042

12 December 2020

inferred from PubMed ID database lookup

Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22083042

12 December 2020

inferred from PubMed ID database lookup

ras oncogenes in human cancer: a review

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22083042

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1038/NRCLINONC.2011.164

1 reference

release_dn6edyvbjrguhox3s3bbazcupe

25 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/dn6edyvbjrguhox3s3bbazcupe

24 November 2022

mapped directly with Wikidata item

1 reference